Amberstone Biosciences Inc

4 articles about Amberstone Biosciences Inc

• Amberstone Biosciences Announces Formation of Scientific Advisory Board

  6/27/2022

  Amberstone Biosciences is announcing the formation of a scientific advisory board comprised of industry leaders in drug delivery, oncology, immunology and pharmaceutical sciences.

• 

  Money on the Move: December 29 – January 4

  1/5/2022

  Here's who rang in the New Year by joining the NASDAQ or raising private equity funds.

• Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics

  1/3/2022

  Amberstone Biosciences, an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, announced the completion of a $12 million Series A financing round.

• 

  Amberstone Biosciences Emerges with $12 Million for Solid Tumor Therapies

  1/3/2022

  With $12 million in hand from a Series A investment round, Amberstone Biosciences aims at cancer with its highly-differentiated tumor microenvironment-activated therapeutic programs.